dbacp02810
General Description
Peptide name : DP1
Source/Organism : Protein transduction domain
Linear/Cyclic : Linear
Chirality : L
Sequence Information
Sequence : KLAKLAKKLAKLAK
Peptide length: 14
C-terminal modification: Linear
N-terminal modification : Free
Non-natural peptide information: None
Activity Information
Assay type : MTT/MTS assay
Assay time : 168h
Activity : LC50 : < 50 µM
Cell line : MCA205
Cancer type : Renal cancer
Other activity : Not Found
Physicochemical Properties
Amino acid composition bar chart :
Molecular mass : 1523.9911 Dalton
Aliphatic index : 1.4
Instability index : -14.971
Hydrophobicity (GRAVY) : -0.071
Isoelectric point : 10.699
Charge (pH 7) : 5.7541
Aromaticity : 0
Molar extinction coefficient (cysteine, cystine): (0, 0)
Hydrophobic/hydrophilic ratio : 1.33333333
hydrophobic moment : -0.324
Missing amino acid : W,T,P,I,M,E,F,D,N,G,C,R,H,Q,S,Y,V
Most occurring amino acid : K
Most occurring amino acid frequency : 6
Least occurring amino acid : L
Least occurring amino acid frequency : 4
Structural Information
3D structure :
Secondary structure fraction (Helix, Turn, Sheet): (1, 0, 0.2)
SMILES Notation: CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)O
Secondary Structure :
| Method | Prediction |
|---|---|
| GOR | HHHHHHHHHHHHHH |
| Chou-Fasman (CF) | HHHHHHHHHHHCCC |
| Neural Network (NN) | HHHHHHHHHHHHHH |
| Joint/Consensus | HHHHHHHHHHHHHH |
Molecular Descriptors and ADMET Properties
Molecular Descriptors: Click here to download
ADMET Properties: Click here to download
Cross Referencing databases
Reference
1 : Mai JC, et al. A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 2001; 61:7709-12.
Literature
Paper title : A proapoptotic peptide for the treatment of solid tumors.
Doi : https://doi.org/Not available
Abstract : We have designed a novel peptide, DP1, which is able to mediate significant induction of apoptosis in solid tumors by local injection. This peptide, comprised of a protein transduction domain (PTD), PTD-5, fused to an antimicrobial peptide, (KLAKLAK)2, was able to trigger rapid apoptosis in a variety of cell lines in vitro, including MCA205 murine fibrosarcomas and human head and neck tumors. Furthermore, direct injection of DP1 into day 7 established MCA205 tumors in C57BL/6 mice resulted in the induction of tumor apoptosis and subsequent reduction in tumor volume. These results suggest that DP1 may be used clinically to treat accessible solid tumors or as an adjuvant therapy in conjunction with radiotherapy, standard chemotherapy, immunotherapy, or surgical debulking.